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Abstract:  
In 2007 started to be carried out for the first time in Portugal a study focused on influenza 
antiviral drug resistance. Three main objectives were established:(1)to determine the antiviral 
profile of influenza viruses to oseltamivir, zanamivir and amantadine;(2)to determine and 
monitor the baseline level of susceptibility along winter seasons and for each influenza 
sub(type);(3)to analyse and characterize the whole genome of viruses that showed phenotypic 
levels of inhibition to neuraminidase inhibitors(NAIs).  
NAIs profile was determined phenotypically, using a fluorescence MUNUNA assay, and 
genotypically by NA and HA sequencing. A total of 340 seasonal viruses(117 A(H3N2),93 
A(H1N1),130 B) were tested for oseltamivir and of 297(112 A(H3N2),68 A(H1N1),117 B) for 
zanamivir. Additionally, 142 A(H1N1)pdm09 viruses were evaluated for both NAIs. Whole 
genome sequencing was performed in 27 of the A(H1N1)pdm09 viruses. Amantadine profile 
was determined through M2 pyrosequencing or conventional sequencing in a total of 205 
seasonal A viruses(138 A(H3N2),84 A(H1N1)) and of 117 A(H1N1)pdm09 viruses. 
Main results are: 
-Resistance to oseltamivir in 27 A(H1N1) seasonal viruses(29%,N=93) from 2007/2008 and 
2008/2009 and in one A(H1N1)pdm09 virus(0.7%,N=142) from 2010/2011. These viruses 
exhibited a highly reduced level of inhibition to oseltamivir by phenotypic analysis (170-650 
IC50 fold-change) and NA H275Y mutation; 
-One suspected case of clinical resistance to oseltamivir with a mixed population of H275Y 
viruses(73,8%H275,26.2%Y275);  
-No resistance to zanamivir; 
-Dual reduced susceptibility to oseltamivir and zanamivir in one B virus(0,85%,N=117) and in 
two A(H1N1)pdm09 viruses(1,41%,N=142). These viruses exhibited a 2-4 IC50 fold-change level 
of inhibition to both NAIs. A mixed population of D197N viruses was found in the B 
virus(56%D197,44%N197) and  the two A(H1N1)pdm09 viruses shared NA I223V and PB2 
V480I mutations;  
-Resistance to amantadine in 49 A(H3N2) viruses(35,5%,N=138) from 2005/2006 to 
2008/2009(46 S31N,3 S31N+V27A), and in all A(H1N1)pdm09 viruses(S31N). 
This 5-year study allowed to establish a technical platform for influenza antiviral drug 
resistance evaluation, to timely detect the emergence of resistant viruses, to acquire know-
how on the natural variation of virus susceptibility, and to contribute for the management of 
cases suspected of clinical resistance. Additionally, it allowed the gathering of a large amount 
of data that will be used in more advanced studies, focused on evolutionary analysis and on 
detailed characterization of specific mutations. 
